AVEO

AVEO Pharmaceuticals / AVEO Oncology

Price

chg

chg neg

quotes and stock data may be delayed 15 minutes

 My Notes

Only BPIQ Pro members can create company notes. Learn more here.

52 wk low

low api

52 wk hi

high api

Cash

$79.0 M

Burn Rate (Qtr)

$8.2 M

Mkt Cap

mkt cap api

Avg Volume

volume api

*cash/burn updated:

Q1 '22

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information.

No drug found

We don't have any drug data for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

Loading Catalysts...

search in progress

Pipeline powered by

AVEO

BPIQ_Logo_RGB-01.jpg

Company Profile

AVEO Oncology (NASDAQ: AVEO) is a cancer therapeutics company committed to discovering and developing targeted therapies designed to provide substantial impact in patients’ lives with clear unmet medical needs. AVEO’s proprietary Human Response PlatformTM provides the company unique insights into cancer biology and is being leveraged in the discovery and clinical development of its cancer therapeutics. For more information, please visit the company’s website at www.aveooncology.com.

Recent Posts

See what the community is saying - click to see full post.